相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616
Christie M. Ballantyne et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)
Why 90 % of clinical drug development fails and how to improve it?
Duxin Sun et al.
ACTA PHARMACEUTICA SINICA B (2022)
Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment
Shakr Ahamad et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Formulation strategies to improve the efficacy of intestinal permeation enhancers
Sam Maher et al.
ADVANCED DRUG DELIVERY REVIEWS (2021)
A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors
Thomas J. Tucker et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Comparison of the effects of the intestinal permeation enhancers, SNAC and sodium caprate (C10): Isolated rat intestinal mucosae and sacs
Caroline Twarog et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2021)
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
Jan Boren et al.
EUROPEAN HEART JOURNAL (2020)
Advances in oral peptide therapeutics
Daniel J. Drucker
NATURE REVIEWS DRUG DISCOVERY (2020)
Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design
Candice Alleyne et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary
Scott M. Grundy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Thirteen decades of peptide synthesis: key developments in solid phase peptide synthesis and amide bond formation utilized in peptide ligation
Da'san M. M. Jaradat
AMINO ACIDS (2018)
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Brian A. Ference et al.
EUROPEAN HEART JOURNAL (2017)
Lipid Lowering Therapy and Circulating PCSK9 Concentration
Tsuyoshi Nozue
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2017)
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cyclic peptide natural products chart the frontier of oral bioavailability in the pursuit of undruggable targets
Matthew R. Naylor et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2017)
Peptide therapeutics: current status and future directions
Keld Fosgerau et al.
DRUG DISCOVERY TODAY (2015)
mRNA display: from basic principles to macrocycle drug discovery
Kristopher Josephson et al.
DRUG DISCOVERY TODAY (2014)
Design of Prodrugs to Enhance Colonic Absorption by Increasing Lipophilicity and Blocking Ionization
Rebecca Nofsinger et al.
PHARMACEUTICALS (2014)
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
Christopher A. Lipinski et al.
ADVANCED DRUG DELIVERY REVIEWS (2012)
Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels Results From 2 Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1 Studies in Healthy Volunteers and Hypercholesterolemic Subjects on Statins
Clapton S. Dias et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease A Mendelian Randomization Analysis
Brian A. Ference et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
Evan A. Stein et al.
LANCET (2012)
Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH
Paola Lo Surdo et al.
EMBO REPORTS (2011)
Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic
Sam Maher et al.
ADVANCED DRUG DELIVERY REVIEWS (2009)
Molecular basis of PCSK9 function
Gilles Lambert et al.
ATHEROSCLEROSIS (2009)
PCSK9 and LDL cholesterol: unravelling the target to design the bullet
Philippe Costet et al.
TRENDS IN BIOCHEMICAL SCIENCES (2008)
Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9
Holly E. Careskey et al.
JOURNAL OF LIPID RESEARCH (2008)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
分享论文
